-
1.发明申请公开(公告)号：US20140106374A1
公开(公告)日：2014-04-17
申请号：US14078241
申请日：2013-11-12
Applicant: Genentech, Inc.
Inventor： Kristi Elkins , Andrew Polson , Allen Ebens , Camelia Adams , Bing Zheng , Jagath R. Junutula , Jo-Anne Hongo , Yan Wu
IPC: G01N33/68
CPC classification number: G01N33/6854 , A61K31/138 , A61K31/4196 , A61K31/454 , A61K31/4745 , A61K31/517 , A61K31/56 , A61K31/568 , A61K31/5685 , A61K31/69 , A61K33/24 , A61K38/19 , A61K39/0011 , A61K39/39533 , A61K39/39558 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/283 , C07K2317/24 , C07K2317/522 , C07K2317/73 , G01N33/574 , G01N33/6857 , Y02A50/473
Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Abstract translation: 本发明涉及可用于治疗哺乳动物造血肿瘤的物质组合物，以及使用这些物质组合物的方法。
-
公开(公告)号：US10604557B2
公开(公告)日：2020-03-31
申请号：US15357545
申请日：2016-11-21
Applicant: Genentech, Inc.
Inventor： Sunil Bhakta , Jagath R. Junutula
IPC: A61K39/395 , C07K16/30 , C07K16/28 , A61K47/48 , A61K39/00 , G01N33/574 , C07K16/00 , A61K51/10 , A61K47/68 , C07K16/32
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
-
公开(公告)号：US10077318B2
公开(公告)日：2018-09-18
申请号：US14851348
申请日：2015-09-11
Applicant: Genentech, Inc.
Inventor： Sunil Bhakta , Hans Erickson , Jagath R. Junutula , Katherine Kozak , Rachana Ohri , Thomas Pillow
IPC: C07K16/00 , C07K16/32 , C07K16/18 , C07K16/28 , C07K16/30 , A61K51/10 , C07K16/40 , G01N33/58 , A61K47/68 , A61K39/00
CPC classification number: C07K16/32 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6849 , A61K47/6869 , A61K51/10 , A61K2039/505 , C07K16/00 , C07K16/18 , C07K16/28 , C07K16/2803 , C07K16/3069 , C07K16/3092 , C07K16/40 , C07K2317/40 , C07K2317/73 , C07K2317/94 , G01N33/582
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
-
公开(公告)号：US20170129963A1
公开(公告)日：2017-05-11
申请号：US15266043
申请日：2016-09-15
Applicant: Genentech, Inc.
Inventor： Sunil Bhakta , Meredith C. Hazen , Jo-Anne S. Hongo , Jagath R. Junutula
CPC classification number: C07K16/30 , C07K16/2809 , C07K2317/31 , C07K2317/565 , C07K2317/73
Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
-
公开(公告)号：US20230130874A1
公开(公告)日：2023-04-27
申请号：US17743727
申请日：2022-05-13
Applicant: Genentech, Inc.
Inventor： Sunil Bhakta , Hans Erickson , Jagath R. Junutula , Katherine Kozak , Rachana Ohri , Thomas Harden Pillow
IPC: C07K16/32 , A61K47/68 , C07K16/18 , C07K16/28 , C07K16/30 , A61K51/10 , C07K16/00 , C07K16/40 , G01N33/58
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
-
Patent Agency Ranking
公开(公告)号：US20170260253A1
公开(公告)日：2017-09-14
申请号：US15357545
申请日：2016-11-21
Applicant: Genentech, Inc.
Inventor： Sunil Bhakta , Jagath R. Junutula
CPC classification number: C07K16/00 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6817 , A61K47/6829 , A61K47/6851 , A61K47/6855 , A61K47/6889 , A61K51/1051 , C07K16/3092 , C07K16/32 , C07K2317/52 , C07K2317/55 , C07K2319/31
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
-
公开(公告)号：US09017951B2
公开(公告)日：2015-04-28
申请号：US13673565
申请日：2012-11-09
Applicant: Genentech, Inc.
Inventor： Kristi Elkins , Andrew Polson , Allen Ebens , Camelia Adams , Bing Zheng , Jagath R. Junutula , Jo-Anne Hongo , Yan Wu
IPC: G01N33/53 , G01N33/574 , A61K39/395 , A61K45/06 , C07K16/28 , A61K31/69 , A61K39/00
CPC classification number: A61K39/3955 , A61K31/69 , A61K39/395 , A61K45/06 , A61K2039/505 , C07K16/283 , C07K2317/24 , C07K2317/92 , A61K2300/00
Abstract: A method of determining the presence of FcRH5 in a biological sample suspected of containing FcRH5 is provided comprising exposing the biological sample to an isolated monoclonal anti-FcRH5 antibody.
Abstract translation: 提供了一种确定怀疑含有FcRH5的生物样品中FcRH5存在的方法，包括将生物样品暴露于分离的单克隆抗FcRH5抗体。
-
公开(公告)号：US08617559B2
公开(公告)日：2013-12-31
申请号：US13682581
申请日：2012-11-20
Applicant: Genentech, Inc.
Inventor： Kristi Elkins , Andrew Polson , Allen Ebens , Camelia Adams , Bing Zheng , Jagath R. Junutula , Jo-Anne Hongo , Yan Wu
IPC: A61K39/00
CPC classification number: G01N33/6854 , A61K31/138 , A61K31/4196 , A61K31/454 , A61K31/4745 , A61K31/517 , A61K31/56 , A61K31/568 , A61K31/5685 , A61K31/69 , A61K33/24 , A61K38/19 , A61K39/0011 , A61K39/39533 , A61K39/39558 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/283 , C07K2317/24 , C07K2317/522 , C07K2317/73 , G01N33/574 , G01N33/6857 , Y02A50/473
Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Abstract translation: 本发明涉及可用于治疗哺乳动物造血肿瘤的物质组合物，以及使用这些物质组合物的方法。
-
公开(公告)号：US20240218050A1
公开(公告)日：2024-07-04
申请号：US18527522
申请日：2023-12-04
Applicant: Genentech, Inc.
Inventor： Sunil Bhakta , Jagath R. Junutula
CPC classification number: C07K16/00 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6817 , A61K47/6829 , A61K47/6851 , A61K47/6855 , A61K47/6889 , A61K51/1051 , C07K16/3092 , C07K16/32 , A61K47/6819 , C07K2317/52 , C07K2317/55 , C07K2319/31
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
-
公开(公告)号：US11873330B2
公开(公告)日：2024-01-16
申请号：US16787280
申请日：2020-02-11
Applicant: Genentech, Inc.
Inventor： Sunil Bhakta , Jagath R. Junutula
CPC classification number: C07K16/00 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6817 , A61K47/6829 , A61K47/6851 , A61K47/6855 , A61K47/6889 , A61K51/1051 , C07K16/3092 , C07K16/32 , A61K47/6819 , C07K2317/52 , C07K2317/55 , C07K2319/31
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.025 seconds)
